Trial Profile

A phase 3 trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Umitrelimorgene autodencel (Primary)
Indications Glioblastoma
Focus Therapeutic Use
Sponsors Immunomic Therapeutics

Most Recent Events

10 Jun 2022 New trial record
07 Jun 2022 According to an Immunomic Therapeutics media release, the company is preparing for phase 3 testing of ITI-1000 for the treatment of glioblastoma multiforme (GBM).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com